Annual report
286A.TEDINET S100XUVY
Period2025-01-01 → 2025-12-31
Filed2026-03-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥24.7bn | 2025-01-01 → 2025-12-31 | Cons. | Net sales |
| Revenue | ¥19.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥18.1bn | 2023-01-01 → 2023-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥16.6bn | 2022-01-01 → 2022-12-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.4bn | 2025-01-01 → 2025-12-31 | Cons. | Operating income |
| Operating income | ¥2.3bn | 2024-01-01 → 2024-12-31 | Cons. | Operating income |
| Ordinary income | ¥2.1bn | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.8bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.9bn | 2023-01-01 → 2023-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥784m | 2022-01-01 → 2022-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.1bn | 2025-01-01 → 2025-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.1bn | 2024-01-01 → 2024-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.8bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.1bn | 2023-01-01 → 2023-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥980m | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.9bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss |
| Total assets | ¥65.1bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥60.1bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥51.0bn | at 2023-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥42.6bn | at 2022-12-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥43.3bn | at 2025-12-31 | Cons. | Liabilities |
| Total liabilities | ¥41.2bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥21.8bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥19.0bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥11.8bn | at 2023-12-31d | Cons. | Net assets |
| Net assets / equity | ¥10.4bn | at 2022-12-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.1bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.2bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥9.1bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.7bn | at 2023-12-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.1bn | at 2022-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.9bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥209m | 2023-01-01 → 2023-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.7bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥406m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.6bn | 2023-01-01 → 2023-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.4bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.8bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.5bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥6.3bn | 2023-01-01 → 2023-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.0bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥78.07 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.4 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.18 | 2023-01-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.8 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥76.75 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥63.12 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥574.26 | at 2025-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥507.67 | at 2024-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥362.04 | at 2023-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥324.44 | at 2022-12-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 31.5% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.9% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.3% | at 2023-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.7% | at 2022-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 14.4% | 2025-01-01 → 2025-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2023-01-01 → 2023-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.3% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,347 | at 2025-12-31 | Cons. | Number of employees |
| Employees | 833 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 769 | at 2023-12-31d | Cons. | Number of employees |
| Employees | 699 | at 2022-12-31d | Cons. | Number of employees |
| Revenue | ¥6.2bn | 2025-01-01 → 2025-12-31 | Standalone | Net sales |
| Revenue | ¥5.6bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥5.4bn | 2023-01-01 → 2023-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.0bn | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.4bn | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | ¥1.4bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | ¥1.4bn | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.1bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.1bn | 2023-01-01 → 2023-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥356m | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥827m | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.2bn | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.4bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | ¥2.3bn | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | ¥1.8bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥709m | 2023-01-01 → 2023-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.3bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥565m | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥40.7bn | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥36.0bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥29.2bn | at 2023-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥22.3bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥23.5bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥21.3bn | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥19.2bn | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥19.4bn | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥16.9bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥10.0bn | at 2023-12-31d | Standalone | Net assets |
| Net assets / equity | ¥9.3bn | at 2022-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.9bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.7bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥6.7bn | at 2024-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥63.87 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.56 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.72 | 2023-01-01 → 2023-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.24 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.91 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥62.79 | 2025-01-01 → 2025-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥57.4 | 2024-01-01 → 2024-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥541.59 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥477.26 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥333.28 | at 2023-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥310.1 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥265.41 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 47.5% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.2% | at 2023-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.7% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 12.5% | 2025-01-01 → 2025-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.7% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2023-01-01 → 2023-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.7% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 37,982,900 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 37,982,900 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,100 | at 2023-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,100 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,100 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 198 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 167 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 130 | at 2023-12-31d | Standalone | Number of employees |
| Employees | 117 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 119 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 70
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2025-01-01 → 2025-12-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-12-31 | 8 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-01-01 → 2025-12-31 | ¥656m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-01-01 → 2025-12-31 | ¥656m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-01-01 → 2025-12-31 | ¥239m |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-12-31 | −¥6m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-12-31 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-12-31 | −¥1.4bn |
| Comprehensive Medical Management Support Businessreportable segment | depreciation | 2025-01-01 → 2025-12-31 | ¥386m |
| Comprehensive Medical Management Support Businessreportable segment | employees | at 2025-12-31 | 319 pure |
| Comprehensive Medical Management Support Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥7.7bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥7.7bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥6m |
| Comprehensive Medical Management Support Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥2.4bn |
| Elderly Care Related Businessreportable segment | depreciation | 2025-01-01 → 2025-12-31 | ¥541m |
| Elderly Care Related Businessreportable segment | employees | at 2025-12-31 | 910 pure |
| Elderly Care Related Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥8.9bn |
| Elderly Care Related Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥8.9bn |
| Elderly Care Related Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥530m |
| Specially Controlled Medical Device Businessreportable segment | depreciation | 2025-01-01 → 2025-12-31 | ¥36m |
| Specially Controlled Medical Device Businessreportable segment | employees | at 2025-12-31 | 60 pure |
| Specially Controlled Medical Device Businessreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥7.5bn |
| Specially Controlled Medical Device Businessreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥7.5bn |
| Specially Controlled Medical Device Businessreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥525m |
| —segment total | depreciation | 2025-01-01 → 2025-12-31 | ¥963m |
| —segment total | employees | at 2025-12-31 | 1289 pure |
| —segment total | revenue | 2025-01-01 → 2025-12-31 | ¥24.1bn |
| —segment total | revenue external | 2025-01-01 → 2025-12-31 | ¥24.1bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥6m |
| —segment total | segment profit | 2025-01-01 → 2025-12-31 | ¥3.5bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-01-01 → 2025-12-31 | ¥965m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-12-31 | ¥24.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-12-31 | ¥24.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥6m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-12-31 | ¥3.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-01-01 → 2024-12-31 | ¥380,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-12-31 | ¥63m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-12-31 | ¥63m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-12-31 | −¥140m |
| Reconciling Itemsreconciling | depreciation | 2024-01-01 → 2024-12-31 | ¥70m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥9m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥9m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥1.2bn |
| Comprehensive Medical Management Support Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥309m |
| Comprehensive Medical Management Support Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥6.4bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥6.4bn |
| Comprehensive Medical Management Support Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥9m |
| Comprehensive Medical Management Support Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥2.8bn |
| Elderly Care Related Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥514m |
| Elderly Care Related Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥6.9bn |
| Elderly Care Related Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥6.9bn |
| Elderly Care Related Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥309m |
| Specially Controlled Medical Device Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥33m |
| Specially Controlled Medical Device Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥6.5bn |
| Specially Controlled Medical Device Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥6.5bn |
| Specially Controlled Medical Device Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥485m |
| —segment total | depreciation | 2024-01-01 → 2024-12-31 | ¥857m |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥19.8bn |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥19.8bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥9m |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥3.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-01-01 → 2024-12-31 | ¥857m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-12-31 | ¥19.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-12-31 | ¥19.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥9m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-12-31 | ¥3.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-12-31 | 8 pure |
| Comprehensive Medical Management Support Businessreportable segment | employees | at 2025-12-31 | 134 pure |
| Elderly Care Related Businessreportable segment | employees | at 2025-12-31 | 6 pure |
| —segment total | employees | at 2025-12-31 | 140 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,719
| Item | Context | Value | Unit |
|---|---|---|---|
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | － | |
| Non regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | － | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 0.400 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | － | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | － | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | － | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | － | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | 0.561 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | － | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | － | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | － | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | － | |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E12328-000ComprehensiveMedicalManagementSupportBusinessReportableSegmentMember | 54086000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_OtherReportableSegmentsMember | 11698000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration | 143946000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 975910000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E12328-000ComprehensiveMedicalManagementSupportBusinessReportableSegmentMember | 703814000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E12328-000ElderlyCareRelatedBusinessReportableSegmentMember | 138387000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 37982900 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 37982900 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 37982900 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 37982900 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 7 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 16 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 80 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 25 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 43 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 6607 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 6778 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 60377 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 1727 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 195745 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 17852 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 297 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 103788 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 379786 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 4300 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.1590 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0045 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.5154 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.0470 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0008 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.2733 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 16000000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.4478 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 4543200 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |